Roche lands Tecentriq trial win, still trails Merck in lung cancer

Roche's Tecentriq plus chemotherapy boosted lung cancer patients' survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group's immunotherapy but still leaving it trailing a rival's drug.

from Reuters: Science News https://ift.tt/2S7VIXI
via IFTTT